New research reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop conventional diet and exercise regimens.
Research printed in a major medical journal shows that while obese individuals frequently drop about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying such drugs should be informed of the risk of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to original mass in about a year and a half.
Analyzing Treatments
The study, which looked at dozens of studies involving thousands of patients, contrasted the effects of these new drugs with older methods.
Scientists note that people who lose weight through lifestyle changes alone typically experience a more gradual creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Regain
Experts suggest the way of the jabs accounts for the accelerated rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the treatment should be considered life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the persistent nature of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs report a intense resurgence of appetite.
"I experienced a trigger flipping and you're instantly extremely hungry," described one woman.
This difficulty is compounded if users have not established sustainable lifestyle or habit changes during treatment.
Widespread Interest
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and long-term success hinges on combined behavioural management.
